Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
GlobeNewswire Inc.
•
•By Na
Verrica Pharmaceuticals announced the first patient dosing in a global Phase 3 clinical trial for YCANTH (VP-102) to treat common warts, a condition affecting approximately 22 million patients in the U.S. with no FDA-approved prescription therapies. The Phase 3 program is based on positive Phase 2 COVE-1 results showing 51% complete clearance of warts. Torii will fund approximately 90% of trial costs on a 50/50 cost-sharing basis, with Verrica's portion covered by future milestones and royalties from Japan.